NASDAQ
14.83USD
+0.93 (+6.69%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
505.6M
P/E
—
EPS
—
Beta
1.89
52W range
7.563-19.6
Day range
13.80–14.83
Open
13.97
Prev close
13.90
Volume
228.5K
Avg volume
189.3K
Dividend
0.00
IPO
2021-04-22
https://seekingalpha.com/article/4926670-neuropace-inc-npce-discusses-fda-feedback-on-pma-supplement-for-indication-expansion-into · 7/29/2026+0.20
https://www.zacks.com/stock/news/2931043/npce-receives-fda-approval-for-ai-powered-ecog-assistant-for-epilepsy?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2931043 · 6/2/2026+0.80
https://www.zacks.com/stock/news/2927695/npce-explains-how-neuropace-s-rns-system-makes-money?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2927695 · 5/27/2026+0.40
https://www.businesswire.com/news/home/20260410149969/en/NeuroPace-to-Present-at-the-25th-Annual-Needham-Virtual-Healthcare-Conference/ · 4/10/2026+0.10
https://www.defenseworld.net/2026/04/05/air-lease-al-its-peers-head-to-head-survey.html · 4/5/2026
https://www.zacks.com/stock/news/2893928/here-s-why-you-should-add-neuropace-stock-to-your-portfolio-now · 4/2/2026+0.60
https://www.zacks.com/stock/news/2881711/npce-rns-system-explained-growth-drivers-and-setup-for-2026?cid=CS-STOCKNEWSAPI-FT-analyst_blog|hybrid-2881711 · 3/10/2026+0.80
https://www.businesswire.com/news/home/20260305082171/en/NeuroPace-to-Present-at-the-Leerink-Global-Healthcare-Conference/ · 3/5/2026+0.10
https://www.fool.com/investing/2026/03/04/why-neuropace-stock-was-inching-higher-on-wednesda/ · 3/4/2026+0.60
https://seekingalpha.com/article/4837938-neuropace-inc-npce-q3-2025-earnings-call-transcript · 11/5/2025+0.00
https://www.zacks.com/stock/news/2703946/neuropace-inc-npce-reports-q2-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2703946 · 8/12/2025-0.40
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
